Paraza Pharma is a fully integrated contract research organization specializing in end-to-end drug discovery and development services. The company provides a comprehensive suite of R&D solutions, leveraging expertise in chemistry, biology, and DMPK to support pharmaceutical and biotech companies, startups, academic institutions, and venture capital firms. Paraza Pharma offers services such as medicinal chemistry, chemical development, biochemistry, cellular biology, pharmacology, and both in vitro and in vivo DMPK, advancing projects from concept to clinical candidate selection. The organization is recognized for its collaborative, client-centric approach, high-quality research, and robust data security practices, including ISO 27001 certification. Paraza Pharma recently expanded its capabilities by acquiring analytical services from adMare BioInnovations, further strengthening its position as a premier partner for drug discovery innovation. Its target clients include companies and institutions seeking to accelerate the development of transformative therapies through expert scientific support and innovative research solutions.